We are live on ! Find out more
AYTU icon

AYTU BioPharma
AYTU

8 hedge funds and large institutions have $8.23M invested in AYTU BioPharma in 2019 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 0 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

18% more capital invested

Capital invested by funds: $6.96M → $8.23M (+$1.26M)

0.04% more ownership

Funds ownership: 0.16% → 0.2% (+0.04%)

33% less funds holding

Funds holding: 12 → 8 (-4)

67% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 6

Holders
8
Holders Change
-4
Holders Change %
-33.33%
% of All Funds
0.16%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
3
Reduced
–
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
+$2.72M
2
Morgan Stanley
Morgan Stanley
New York
+$38.2K
3
SC
Searle & Co
Connecticut
+$21.7K
4
BlackRock
BlackRock
New York
+$4.42K
5
UBS Group
UBS Group
Switzerland
+$3.07K

Top Sellers

Rank Fund Capital Flow
1
WC
Wexford Capital
Florida
-$123K
2
Acadian Asset Management
Acadian Asset Management
Massachusetts
-$58K
3
VF
Virtu Financial
New York
-$36K
4
Citadel Advisors
Citadel Advisors
Florida
-$15K
5
Victory Capital Management
Victory Capital Management
Texas
-$4K

AYTU Hedge Fund Activity: Q4 2019 in Review

8 of the 5,092 institutional investors tracked by Wall St. Rank reported a position in AYTU BioPharma (AYTU) for Q4 2019, worth a combined $8.23M — up 18% from $6.96M a quarter earlier.

Sellers outnumbered buyers: 6 funds closed out of AYTU and 2 opened new positions — a net loss of 4 holders — while 0 trimmed existing stakes and 3 added.

The largest buyer was Armistice Capital, adding an estimated $2.72M. The largest seller was Wexford Capital, exiting entirely with an estimated $123K sold.

  • 8 institutional investors held AYTU BioPharma (AYTU) as of Q4 2019, down from 12 in Q3 2019.
  • Funds reported $8.23M of AYTU BioPharma stock for Q4 2019, up 18% quarter-over-quarter.
  • 2 funds opened new AYTU BioPharma positions in Q4 2019 and 6 closed out, a net change of -4 holders.
  • The largest AYTU BioPharma buyer in Q4 2019 was Armistice Capital, an estimated $2.72M added.
  • The largest AYTU BioPharma seller in Q4 2019 was Wexford Capital, an estimated $123K sold.

Based on aggregated 13F filings for Q4 2019.